David E.I. Pyott, MBA has served as a member of our Board of Directors since February 2026. Mr. Pyott served as the Chief Executive Officer of Allergan, Inc., or Allergan, a global specialty pharmaceutical and medical device company, from January 1998 to March 2015 and as the Chair of Allergan's board of directors from March 2001 until March 2015. Prior to Allergan, Mr. Pyott served as the Head of the Nutrition Division at Novartis AG, a global healthcare company, and as a member of the Executive Committee of Switzerland-based Novartis AG. Mr. Pyott has also served as a director of Alnylam Therapeutics, Inc. since December 2015 and Pliant Therapeutics, Inc. since January 2021 (Mr. Pyott has decided not to stand for re-election on the Pliant Therapeutics, Inc. board of directors). Previously, Mr. Pyott served as a director of BioMarin Pharmaceutical Inc. from January 2016 to May 2025 and as a member of the Supervisory Board of Royal Philips in the Netherlands from May 2015 to May 2025. Mr. Pyott currently serves as chairperson of the Governing Board of the London Business School, a Trustee of the California Institute of Technology, and Vice President of the Ophthalmology Foundation. He holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School. Mr. Pyott is qualified to serve on our Board due to his substantial successful executive operational experience in the pharmaceutical industry and public company governance experience from serving on the boards of several large public companies.